Encouraged by our efficient, precise PE and ABE correction of ATP1A3 mutations in AHC-patient-derived iPSCs, we next examined how precision gene editing might mitigate AHC pathology in vivo. The gene discussed is ATP1A3; the disease is alternating hemiplegia of childhood.